• S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?
    Aug 2 2022

    Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969525). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://www.medscape.com/resource/schizophrenia

    Understanding the Effects of Antipsychotics on Appetite Control https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762106/

    Food and Drug Administration's Obesity Drug Guidance Document https://www.ahajournals.org/doi/10.1161/circulationaha.111.028381

    Risk of Weight Gain for Specific Antipsychotic Drugs: A Meta-analysis https://www.nature.com/articles/s41537-018-0053-9

    Diabetes and Schizophrenia https://link.springer.com/article/10.1007/s11892-015-0704-4

    Brain Insulin Action: Implications for the Treatment of Schizophrenia https://www.sciencedirect.com/science/article/abs/pii/S0028390819301960?via%3Dihub

    Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis -- A Longitudinal Study https://academic.oup.com/schizophreniabulletin/article-abstract/47/6/1772/6291438

    Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission https://pubmed.ncbi.nlm.nih.gov/25004198/#:~:text=Conclusions%3A%20Body%20mass%20index%20was,be%20explored%20in%20prospective%20studies

    Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort https://pubmed.ncbi.nlm.nih.gov/30257079/

    Incidence and Severity of Tardive Dyskinesia Increase With Age https://jamanetwork.com/journals/jamapsychiatry/article-abstract/492775

    Extrapyramidal Symptoms With Atypical Antipsychotics: Incidence, Prevention and Management https://reference.medscape.com/medline/abstract/15733025

    Show more Show less
    25 mins
  • S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing
    Aug 2 2022

    Drs John Kane and Stefan Leucht discuss the effectiveness and optimal dosing of antipsychotic medications in the treatment of schizophrenia.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969527). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Toward a Phenomenological Psychotherapy for Schizophrenia https://www.karger.com/Article/FullText/500163

    APA Releases New Practice Guideline on Treatment of Patients with Schizophrenia https://www.psychiatry.org/newsroom/news-releases/apa-releases-new-practice-guideline-on-treatment-of-patients-with-schizophrenia

    Pharmacological Treatments for First-Episode Schizophrenia https://academic.oup.com/schizophreniabulletin/article/31/3/705/1894509?login=false

    Putting the Efficacy of Psychiatric and General Medicine Medication Into Perspective: Review of Meta-analyses https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/putting-the-efficacy-of-psychiatric-and-general-medicine-medication-into-perspective-review-of-metaanalyses/39C15F3428BDD1F8A4C152B67C06A5A6

    The Nature of Relapse in Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855

    20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29621900/

    Amisulpride and Olanzapine Followed by Open-Label Treatment With Clozapine in First-Episode Schizophrenia and Schizophreniform Disorder (OPTiMiSE): A Three-Phase Switching Study https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30252-9/fulltext

    Clozapine https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

    Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study https://www.psychiatrist.com/jcp/schizophrenia/lurasidone-in-early-nonresponding-schizophrenia/

    Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19010034

    Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2783296

    Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2725088

    Show more Show less
    26 mins
  • S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?
    Sep 13 2022

    Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

    The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N

    Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x

    Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/

    Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/

    Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

    Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/

    Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022

    Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016

    Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long

    A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772

    A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950

    A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640

    Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336

    Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591

    Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015

    Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/

    Show more Show less
    23 mins
  • S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?
    Oct 5 2022

    Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969529). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://www.medscape.com/resource/schizophrenia

    Schizophrenia Practice Essentials https://emedicine.medscape.com/article/288259-overview

    The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.163.3.426

    Comprehensive Review of the Research Employing the Schizophrenia Cognition Rating Scale (SCoRS) https://www.sciencedirect.com/science/article/pii/S0920996419302178

    Using a Meta-cognitive Wisconsin Card Sorting Test to Measure Introspective Accuracy and Biases in Schizophrenia and Bipolar Disorder https://www.sciencedirect.com/science/article/abs/pii/S0022395621003903

    Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256669/

    Brain HQ https://www.brainhq.com/

    Training Engagement, Baseline Cognitive Functioning, and Cognitive Gains With Computerized Cognitive Training: A Cross-Diagnostic Study https://europepmc.org/article/pmc/pmc6889599

    Efficacy and Safety of the Novel Glycine Transporter Inhibitor BI 425809 Once Daily in Patients With Schizophrenia: A Double-Blind, Randomised, Placebo-Controlled Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S2215-0366(20)30513-7

    A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study https://clinicaltrials.gov/ct2/show/NCT05211947

    Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients With Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105423/

    Karunatx.com. KarXT https://karunatx.com/pipeline-programs/karxt/

    F46. The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1) https://pmg.joynadmin.org/documents/1007/6247485871767404791c9d14.pdf

    Cognitive Training and Supported Employment for Persons With Severe Mental Illness: One-Year Results From a Randomized Controlled Trial https://academic.oup.com/schizophreniabulletin/article/31/4/898/1877695

    Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

    Why Treating Early, Treating Well, and Treating for Life Is Important in Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991981/

    Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496792/

    P515. Genomic Analyses of Schizophrenia and Bipolar Disorder Patients With Very Poor Outcomes https://www.researchgate.net/publication/360255195_P515_Genomic_Analyses_of_Schizophrenia_and_Bipolar_Disorder_Patients_With_Very_Poor_Outcomes

    Challenges in Assessment of Daytime Sleepiness in Cognitively Impaired Populations Can Be Bypassed Through Use of Ecological Momentary Assessment https://scholarship.miami.edu/esploro/outputs/report/Challenges-in-Assessment-of-Daytime-Sleepiness/991031600661502976

    Evidence for Avolition in Bipolar Disorder? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141033/

    Show more Show less
    25 mins
  • S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?
    Nov 9 2022

    Drs John Kane and Anil Malhotra discuss neuroimaging and connectivity between various regions of the brain in patients with schizophrenia and how it impacts the pathophysiology and treatment response.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969530). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://www.medscape.com/resource/schizophrenia

    Diffusion Tensor Imaging Measures of White Matter Compared to Myelin Basic Protein Immunofluorescence in Tissue Cleared Intact Brains https://www.sciencedirect.com/science/article/pii/S235234091630779X?via%3Dihub

    Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845897/

    Dissecting Heterogeneity of Treatment Response of First Episode Schizophrenia https://grantome.com/grant/NIH/P50-MH080173-05

    The M1/M4 Preferring Muscarinic Agonist Xanomeline Modulates Functional Connectivity and NMDAR Antagonist-Induced Changes in the Mouse Brain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115158/

    Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence From Preclinical Models and Clinical Studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704992/

    ECT and Other Procedures for Schizophrenia https://www.webmd.com/schizophrenia/electroconvulsive-therapy

    Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2014.13060787

    Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

    Psychosis Relapse During Treatment With Long-Acting Injectable Antipsychotics in Individuals With Schizophrenia-Spectrum Disorders: An Individual Participant Data Meta-analysis https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30264-9/fulltext

    North American Prodrome Longitudinal Study https://napls.ucsf.edu/

    Association Between Residential Instability at Individual and Area Levels and Future Psychosis in Adolescents at Clinical High Risk From the North American Prodrome Longitudinal Study (NAPLS) Consortium https://www.sciencedirect.com/science/article/abs/pii/S0920996421003959?via%3Dihub

    Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2792519

    Brain Disease and Psychiatric Illness: When Should a Psychiatrist Order a CAT Scan? https://ajp.psychiatryonline.org/doi/10.1176/ajp.141.12.1521

    Transcranial Magnetic Stimulation for Positive Symptoms in Schizophrenia: A Systematic Review https://www.karger.com/Article/FullText/502148

    Show more Show less
    22 mins
  • S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It
    Dec 7 2022

    Drs John Kane and Jose Rubio-Lorente discuss relapse in schizophrenia — why it occurs, how often it occurs, and what we can do about it.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969531). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://www.medscape.com/resource/schizophrenia

    Schizophrenia Clinical Presentation https://emedicine.medscape.com/article/288259-clinical

    Natural Course of Schizophrenic Disorders: A 15-Year Follow-up of a Dutch Incidence Cohort https://academic.oup.com/schizophreniabulletin/article/24/1/75/1878027

    Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder https://jamanetwork.com/journals/jamapsychiatry/fullarticle/204795

    Five-Fold Increased Risk of Relapse Following Breaks in Antipsychotic Treatment of First Episode Psychosis https://www.sciencedirect.com/science/article/abs/pii/S0920996416304376?via%3Dihub

    Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530382/

    Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients With Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710250

    Long-Acting Injectable Versus Oral Antipsychotics for the Maintenance Treatment of Schizophrenia: A Systematic Review and Comparative Meta-analysis of Randomised, Cohort, and Pre-Post Studies https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00039-0/fulltext

    Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364341/

    Psychosis Relapse During Treatment With Long-Acting Injectable Antipsychotics in Individuals With Schizophrenia-Spectrum Disorders: An Individual Participant Data Meta-analysis https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30264-9/fulltext

    The Pharmacological Treatment of Schizophrenia: How Far Have We Come? https://onlinelibrary.wiley.com/doi/full/10.1002/pcn5.13

    Striatal Functional Connectivity in Psychosis Relapse: A Hypothesis Generating Study https://www.sciencedirect.com/science/article/pii/S092099642100222X?via%3Dihub

    Show more Show less
    24 mins
  • S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment
    Mar 22 2023

    Drs John M. Kane and Jonathan Meyer discuss treatment-resistant schizophrenia, how common it is, how to detect and manage it, and how delays in the initiation of treatment negatively affect patients.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

    Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives https://pubmed.ncbi.nlm.nih.gov/30170114/

    Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders https://pubmed.ncbi.nlm.nih.gov/33043960/

    Mortality in People With Schizophrenia: A Systematic Review and Meta-analysis of Relative Risk and Aggravating or Attenuating Factors https://pubmed.ncbi.nlm.nih.gov/35524619/

    Pharmacological Interventions for Clozapine-Induced Hypersalivation https://pubmed.ncbi.nlm.nih.gov/18646130/

    The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders https://pubmed.ncbi.nlm.nih.gov/25154620/

    Antipsychotic Plasma Levels in the Assessment of Poor Treatment Response in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29072776/

    Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology https://pubmed.ncbi.nlm.nih.gov/27919182/

    An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels https://pubmed.ncbi.nlm.nih.gov/34911124/

    FDA Strengthens Warning That Untreated Constipation Caused by Schizophrenia Medicine Clozapine (Clozaril) Can Lead to Serious Bowel Problems https://www.fda.gov/drugs/drug-safety-and-availability/fda-strengthens-warning-untreated-constipation-caused-schizophrenia-medicine-clozapine-clozaril-can

    Cariprazine https://reference.medscape.com/drug/vraylar-cariprazine-999874

    Lumateperone https://reference.medscape.com/drug/caplyta-lumateperone-1000316

    Lurasidone https://reference.medscape.com/drug/latuda-lurasidone-999605

    Show more Show less
    26 mins
  • S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization
    Mar 22 2023

    Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984482). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Schizophrenia https://emedicine.medscape.com/article/288259-overview

    The Nature of Relapse in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/23394123/

    What Is the Risk-Benefit Ratio of Long-term Antipsychotic Treatment in People With Schizophrenia? https://pubmed.ncbi.nlm.nih.gov/29856543/

    Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

    Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study https://pubmed.ncbi.nlm.nih.gov/34129663/

    Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia https://pubmed.ncbi.nlm.nih.gov/36791360/

    Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-analysis of Mirror-Image Studies https://pubmed.ncbi.nlm.nih.gov/24229745/

    Antipsychotic Use Among Persons With Schizophrenia in Sweden and Finland, Trends and Differences https://pubmed.ncbi.nlm.nih.gov/33331804/

    Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-Acting Injectable Antipsychotics in Clinically Stabilized Patients With Schizophrenia: A Re-analysis of Individual Participant Data https://pubmed.ncbi.nlm.nih.gov/34355232/

    Show more Show less
    24 mins